摘要
为观察前列腺癌患者血唾液酸（ＳＡ）与病情、疗效及血清ＰＳＡ的关系，按血ＰＳＡ高低将病人分为３组：Ａ组（治疗前，１７例）血ＰＳＡ≥５０μｇ／Ｌ，７０７％为临床Ｃ、Ｄ１、Ｄ２期，病情进展，前列腺症状或骨痛明显。Ｂ组（治疗前，６例）血ＰＳＡ８～３７μｇ／Ｌ，临床分期为Ｃ、Ｄ期，占５０％。Ｃ组（治疗后，８例）血ＰＳＡ＜４μｇ／Ｌ，除临床Ｃ期１例，余均为临床Ｂ期术后，病愈或明显好转。血ＳＡ均值，Ａ组为３０８ｍｍｏｌ／Ｌ，大于Ｂ组２８１ｍｍｏｌ／Ｌ及Ｃ组２１４ｍｍｏｌ／Ｌ；Ａ、Ｃ间有非常显著性差异（Ｐ＜０００１），尿ＳＡ结果同血ＳＡ，Ｐ＜００５。此外，血ＰＳＡ与血ＳＡ（或尿ＳＡ）密切相关，Ｐ＜００１。同为阳性（或阴性）一致率血ＳＡＰＳＡ为８１６％，尿ＳＡＰＳＡ为７２２％。本实验所用“一步法”简便快速，血ＳＡ敏感性１０００％，特异性７８１％，不需进口试剂或设备，有助于前列腺癌的检出与病情疗效追踪观察。
To assess the value of sialic acid (SA) as a tumor activity marker in prostatic cancer, serum SA (SSA) or urine SA (USA) were measured with simultaneous assay of prostate specific antigen (PSA) both before and under treatment with flutamide, before and after prostatectomy or orchiectomy. The mean level of SSA was higher in group A(17 advanced cases before treatment)than in group B (6 milder cases before treatment )and group C (8 cases cured or markedly improved after treatment)( P <0 001).The same was true with USA ( P <0.05).Moreover, serum PSA was closely associated with SSA or USA ( P <0.001).The simultaneous positive or negative rate of serum SA and PSA was 81.6% and that of urine SA and PSA 72.2%.The one step resorcinol method used was simple, quick and nonexpensive with a 100% sensitivity and 78.1% specificity rafe for SSA and therefore would be helpful in the evaluation of the development of the disease, efficacy of the treatment and the detection of reccurrence especially when PSA assay was not available.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1997年第2期103-106,共4页
Chinese Journal of Urology
